$16.16
2.30% today
Nasdaq, Nov 26, 04:47 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Target price 2024 - Analyst rating & recommendation

ACADIA Pharmaceuticals Inc. Classifications & Recommendation:

Buy
65%
Hold
30%
Sell
5%

ACADIA Pharmaceuticals Inc. Price Target

Target Price $25.11
Price $16.54
Potential
Number of Estimates 19
19 Analysts have issued a price target ACADIA Pharmaceuticals Inc. 2025 . The average ACADIA Pharmaceuticals Inc. target price is $25.11. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 13 Analysts recommend ACADIA Pharmaceuticals Inc. to buy, 6 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ACADIA Pharmaceuticals Inc. stock has an average upside potential 2025 of . Most analysts recommend the ACADIA Pharmaceuticals Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 726.44 973.10
40.45% 33.95%
EBITDA Margin -9.34% 12.30%
78.20% 231.73%
Net Margin -8.47% 12.43%
80.34% 246.71%

20 Analysts have issued a sales forecast ACADIA Pharmaceuticals Inc. 2024 . The average ACADIA Pharmaceuticals Inc. sales estimate is

$973m
Unlock
. This is
4.72% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.1b 14.09%
Unlock
, the lowest is
$948m 1.97%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $726m 40.45%
2024
$973m 33.95%
Unlock
2025
$1.0b 7.83%
Unlock
2026
$1.2b 11.05%
Unlock
2027
$1.3b 10.34%
Unlock
2028
$1.4b 10.57%
Unlock

6 Analysts have issued an ACADIA Pharmaceuticals Inc. EBITDA forecast 2024. The average ACADIA Pharmaceuticals Inc. EBITDA estimate is

$120m
Unlock
. This is
3.89% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$204m 63.82%
Unlock
, the lowest is
$65.8m 47.17%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-67.8m 69.39%
2024
$120m 276.46%
Unlock
2025
$129m 7.50%
Unlock
2026
$210m 63.30%
Unlock
2027
$672m 219.67%
Unlock
2028
$797m 18.70%
Unlock

EBITDA Margin

2023 -9.34% 78.20%
2024
12.30% 231.73%
Unlock
2025
12.26% 0.33%
Unlock
2026
18.03% 47.06%
Unlock
2027
52.25% 189.79%
Unlock
2028
56.09% 7.35%
Unlock

19 ACADIA Pharmaceuticals Inc. Analysts have issued a net profit forecast 2024. The average ACADIA Pharmaceuticals Inc. net profit estimate is

$121m
Unlock
. This is
5.54% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$195m 51.95%
Unlock
, the lowest is
$69.9m 45.45%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-61.5m 72.39%
2024
$121m 296.57%
Unlock
2025
$127m 4.87%
Unlock
2026
$185m 45.55%
Unlock
2027
$269m 45.92%
Unlock
2028
$352m 30.75%
Unlock

Net Margin

2023 -8.47% 80.34%
2024
12.43% 246.71%
Unlock
2025
12.09% 2.74%
Unlock
2026
15.85% 31.10%
Unlock
2027
20.96% 32.24%
Unlock
2028
24.79% 18.27%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.37 0.73
72.39% 297.30%
P/E 22.74
EV/Sales 2.30

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast for earnings per share. The average ACADIA Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.73
Unlock
. This is
5.19% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$1.17 51.95%
Unlock
, the lowest is
$0.42 45.45%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.37 72.39%
2024
$0.73 297.30%
Unlock
2025
$0.76 4.11%
Unlock
2026
$1.11 46.05%
Unlock
2027
$1.62 45.95%
Unlock
2028
$2.12 30.86%
Unlock

P/E ratio

Current 21.41 187.67%
2024
22.74 6.21%
Unlock
2025
21.69 4.62%
Unlock
2026
14.90 31.30%
Unlock
2027
10.21 31.48%
Unlock
2028
7.81 23.51%
Unlock

Based on analysts' sales estimates for 2024, the ACADIA Pharmaceuticals Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.41 54.78%
2024
2.30 4.65%
Unlock
2025
2.13 7.26%
Unlock
2026
1.92 9.95%
Unlock
2027
1.74 9.37%
Unlock
2028
1.57 9.56%
Unlock

P/S ratio

Current 2.96 48.86%
2024
2.83 4.51%
Unlock
2025
2.62 7.26%
Unlock
2026
2.36 9.95%
Unlock
2027
2.14 9.37%
Unlock
2028
1.94 9.55%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today